Tag Archives: adalimumab

March, 2016

  • 2 March

    Merck KGaA Initiates Phase 3 Study of its Humira Biosimilar

    DARMSTADT, Germany, March 2, 2016 /PRNewswire/ — Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the initiation of a global phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck KGaA, Darmstadt, Germany’s progress …

January, 2016

  • 27 January

    FDA Accepts Amgen’s BLA for its Humira Biosimilar

    THOUSAND OAKS, Calif., Jan. 25, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab). “If approved, we believe ABP 501 could serve as an important additional approved …

December, 2015

October, 2015